Scientific article
Open access

Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination

Published inFrontiers in immunology, vol. 14, 1172851
Publication date2023
First online date2023-07-03

Multiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil. As participants were randomised to BCG vaccination or placebo in the preceding 0-6 months as part of the BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial, we also investigated the influence of recent BCG vaccination on antibody responses to these COVID-19 vaccines. Twenty-eight days after the second dose of each vaccine, ChAdOx1-S induced a stronger anti-spike IgG response than CoronaVac vaccination. Recent BCG vaccination did not impact IgG antibody responses to ChAdOx1-S or CoronaVac.

  • BCG
  • COVID-19
  • ChAdOx1-S
  • CoronaVac
  • Antibody
  • Vaccine
  • Humans
  • COVID-19 Vaccines
  • BCG Vaccine
  • Antibody Formation
  • COVID-19 / prevention & control
  • Vaccination
  • ChAdOx1 nCoV-19
  • Immunoglobulin G
Affiliation Not a UNIGE publication
Citation (ISO format)
MESSINA, Nicole L et al. Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination. In: Frontiers in immunology, 2023, vol. 14, p. 1172851. doi: 10.3389/fimmu.2023.1172851
Main files (1)
Article (Published version)
ISSN of the journal1664-3224

Technical informations

Creation08/10/2023 9:08:12 AM
First validation11/14/2023 9:29:01 AM
Update time11/14/2023 9:29:01 AM
Status update11/14/2023 9:29:01 AM
Last indexation05/06/2024 5:20:39 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack